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From a search of the Health Economics Evaluations
Database (HEED), 301 studies relating to diabetes-re-
lated interventions were identified. Of these, 223 stud-
ies contained some original data, i.e., were applied stud-
ies. Over the 1990s, the number of studies undertaken
in this area appears to be increasing year on year, and
more of the studies are applicable to the USA than to all
other countries combined. Most studies are peer re-
viewed, the main type of analysis is cost-consequence,
and the interventions most often assessed are pharma-
ceutical and care services. Both the public and the pri-
vate sectors sponsor many of these studies. However,
only a fraction of these studies appear to accord with
guidance for good economic evaluation. For example,
when the search criteria were tightened to capture only
those studies that consider both outcomes and costs,
173 studies were identified. Narrowing the search crite-
ria to capture only those studies that were based on ran-
domized controlled trial (RCT) or modeling data—the
methods recommended by the US Panel and the Na-
tional Institute of Clinical Excellence (NICE)—reduced
the sample to 56 studies. With specific focus on those
studies that evaluated pharmaceuticals, only the model-
ing approach appeared to show any compliance at all
with another key recommendation of the existing guid-
ance on methods; that of using outcome measures that
are applicable to a long-term time horizon.
Though modeling does offer certain advantages over
RCTs (for example, a larger range of comparators can
be more readily incorporated, long-term outcome mea-
sures can be more easily and inexpensively estimated),
modeling results have less internal validity. Also, mod-
eling in itself relies on good RCT data. Therefore, the
results of economic evaluations should be interpreted
with care, irrespective of whether they are principally
based on RCT or model-based methods.
 
Keywords:
 
 descriptive review, diabetes, economic evalu-
ation, guidance.
 
Introduction
 
The economic evaluation of health care interven-
tions is entering the public policy domain in many
countries. For example, in the UK context, the re-
cently established National Institute for Clinical
Excellence (NICE) has a remit to gather clinical
and cost-effectiveness evidence on selected health
care interventions. The interventions are selected
on the basis of whether their utilization varies
markedly throughout the UK, or on whether they
are associated with substantial resource implica-
tions. The clinical and cost-effectiveness informa-
tion is then used by NICE to determine whether
they are to recommend the intervention for use by
frontline National Health Service (NHS) staff.
One of the interventions that has been chosen for
appraisal by NICE is glitazones (thiazolidinediones)
for type II diabetes. Therefore, in the UK context
(and beyond), a discussion of economic evaluation
is pertinent to those who manufacture, use and re-
imburse interventions against diabetes. The objec-
tive of this article is to provide a descriptive review
of some of the key features associated with the
production, content and dissemination of previ-
ously published economic evaluations of diabetes
interventions. An attempt is then made to assess
the extent to which these evaluations comply with
some of the features of study design recommended
by existing guidance on health economic evaluation.
 
Descriptive Review
 
Literature Search
 
The March 2000 version of the Health Economics
Evaluations Database (HEED) was used [1]. HEED
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contains reviews of evaluations of health care in-
terventions that hold some information on cost or
resource requirements. By implication, HEED con-
tains reviews of all of the standard forms of eco-
nomic evaluation, and cost-consequences, cost of
illness and cost analyses. This study was not in-
tended to be a systematic review, though the arti-
cles selected for inclusion on HEED are gathered
through a comprehensive search of the literature,
which includes the main medical search engines
such as Medline and Embase. We aimed to gain a
general idea of the features of diabetes-related eco-
nomic evaluations, and HEED offers a consistent
set of across-study data on the features in which
we were interested.
In the general search of the diabetes-related liter-
ature, the only search field that was used was that
for ICD-9 codes. The code for diabetes (ICD-9 250)
was entered, and 301 articles were identified. The
distribution of the type of studies that have been
published is presented in Fig. 1, and demonstrates
that the majority of studies are applied; that is,
they contain some original data. “Review” refers to
those studies that are reviews of published applied
studies. Since many of the applied studies would
also be included in the review articles, the analysis
was confined to only those articles that contain
some original data. Thus, the 223 applied studies
form our initial focus of attention.
 
Study Date and Place
 
Figure 2 indicates that there is an increasing trend
in the number of published evaluations of diabetes
interventions. There is a caveat in that HEED is a
comprehensive database of only the post 1992 lit-
erature; this does not, however, disguise the gener-
ally increasing trend. The small number of studies
published in 1999 is explained by the fact that
HEED will incorporate many of its entries for
1999 throughout the year 2000.
It can be observed from Fig. 3 that there were
more studies with data applicable to the USA (i.e.,
with data collected in the USA) than any other
country. Indeed, more studies are applicable to the
USA than all of the other countries combined.
 
Medium of Publication and Type of Analysis
 
Figure 4 shows that most of the evaluations were
published in peer-reviewed journals, which sug-
gests that whilst their quality is not absolutely
guaranteed, they have been through some process
of quality control.
As observed in Fig. 5, the total number of anal-
yses appears to exceed 223. This is because some
studies contained more than one type of analysis.
This phenomenon is also applicable to some of the
other criteria that will be descriptively presented
in the following figures. Cost-consequences analy-
Figure 1 Type of study.
Figure 2 Year of study.
Figure 3 Country to which study applies.
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ses predominate. These studies do not express
their results as a ratio, and are often clinical stud-
ies with only a small amount of cost data in-
cluded. In some cost-consequences studies, there is
no explicit comparator to the study intervention.
These can be classified as “cost-outcome descrip-
tions” rather than as full economic evaluations
[2]. Those analyses that have a firm foundation in
economic theory (i.e., cost-effectiveness, cost-util-
ity, cost-benefit and cost-minimization analyses),
comprise a relatively small proportion of the total
number of analyses undertaken.
 
Intervention Assessed and Study Sponsor
 
Figure 6 illustrates that pharmaceuticals and care
services (e.g., inpatient vs. outpatient care) are the
areas that form the main foci of attention in the
economic evaluation of diabetes-related interven-
tions. It is interesting to note that the government
financially sponsors more of the evaluations than
does the pharmaceutical industry (Fig. 7), though
sponsorship sources are distributed fairly evenly
across government, industry, research funding bod-
ies, charities and health care institutes.
 
Compliance with Guidance
 
With over 300 studies in total, there is a wealth of
information on the costs and outcomes of diabetes
interventions. An attempt is now made to explore
the extent to which these studies comply with some
of the important criteria given by existing guidance
on what constitutes good economic evaluation.
Focussing on the applied studies, the sample was
narrowed to those studies that considered both the
outcomes and costs of an intervention. This is be-
cause the outcome and cost implications of an inter-
vention are both required for the decision-maker to
reach an informed decision from an economic per-
spective. From this perspective, decision makers
should be concerned with the relative levels of health
gain that can be generated by using resources in dif-
Figure 4 Medium of publication.
Figure 5 Type of analysis.
Figure 6 Intervention assessed.
Figure 7 Source of sponsorship.
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ferent ways; for example, how much health is gained
or forgone by committing health care resources to
one use rather than another? Those studies that
focussed on costs only—i.e., cost or cost of illness
analyses—were excluded, as the level of health gain
generated by investing in health care interventions
cannot be ascertained from these types of study. The
resulting sample comprised 173 studies.
Two sources detailing the appropriate design
that a study should take were consulted. As Table
1 indicates, these were the report by the US Panel
on Cost-Effectiveness in Health and Medicine [3],
and the guidance on submissions to NICE [4]. The
US Panel expressed a preference for economic
evaluations based on effectiveness data from ran-
domized controlled trials (RCTs), the study design
least prone to bias [3]. Also, according to the US
Panel the data on outcomes and costs should ide-
ally be drawn from a common primary study.
Whilst the NICE guidance does not explicitly ex-
press that the data on outcomes and costs should
be drawn from a common study, the RCT is re-
garded as the appropriate study design for gener-
ating evidence on clinical effectiveness. Both the
US Panel and the NICE guidance state that model-
ing should be used when data has been gathered
from more than one source. It should be noted,
however, that guidance relating to very specific as-
pects of economic evaluation, such as that pertain-
ing to discount rates or sensitivity analyses, is be-
yond the scope of this paper. The focus here does
not extend beyond those features outlined in Ta-
ble 1. RCTs and modeling are both recommended
by the guidance. Let us briefly outline the pros
and cons of these types of design.
 
Modeling vs. RCT-Based Evidence
 
The usefulness of RCTs can be questioned on the
basis that they produce results that may not be rel-
evant to the practical clinical environment in
which treatment decisions are made. The conduct
of RCTs is normally governed by strict protocols,
which may involve the use of resources that are
not typical of clinical practice; for example, in pa-
tient monitoring. Moreover, the selection of pa-
tients in RCTs may not be representative of those
seen in practice, with respect to variables such as
age, gender and ethnic composition, and comor-
bidities. The high internal validity of RCT data, in
terms of the ability to attribute an observed change
in clinical outcome to the intervention under inves-
tigation, is accompanied by potentially low exter-
nal validity, or the ability to generalize the findings
to other settings. Modeling techniques have been
adopted in economic evaluation as a means of ad-
dressing this problem. While modeling is viewed by
some as an inadequate substitute for high quality
RCT data [5], others perceive modeling as an indis-
pensable aid to the decision-making process [6].
An intermediate position has been taken by
those who argue that attempts should be made to
improve the external validity of RCTs by making
them more relevant to the clinical context in which
real-world treatment is administered [7]. These “im-
proved” RCTs are called “pragmatic trials”, and
have the following features [7]:
• Patients who are typical of the normal case-
load are enrolled in the trial;
• The therapy of interest is compared with cur-
rently administered care;
 
Table 1
 
Requirements of the US Panel and NICE
 
Study 
characteristic US Panel NICE
Overall design Outcome probability values should be selected from the
best designed (and least biased) sources that are relevant to the 
question and population under study. Ideally, data on the costs 
and effects of an intervention should both be collected from the 
same properly designed primary study. When data are gathered 
from separate sources, the analyst will generally rely on 
mathematical or simulation models
Data to support claims for clinical effectiveness should, 
ideally, be derived from randomized controlled trials. In 
those instances where no formal(head-to-head) 
comparisons have been made, manufacturers and 
sponsors should consider modeling comparisons with 
reference to the published literature
Comparator As a rule, and as a minimum, studies from the societal 
perspective should compare the intervention to existing practice 
for addressing the health problem
As a rule of thumb comparisons should be made with 
current standard practice, which may be a similar 
technology or an alternative therapeutic (or diagnostic) 
approach
Outcomes Measures that capture both quantity (duration) of life and quality 
of life . . . are best suited for use
Benefits may include reductions in morbidity or 
mortality, improved quality of life, or other measures of 
positive outcome
Time horizon The time horizon of the analysis for a cost-effectiveness study 
should extend far enough into the future to capture the major 
health and economic outcomes
The end-points used in assessing clinical effectiveness 
should be appropriate for the condition and may need 
to encompass changes in mortality and morbidity as 
well as quality of life
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• The settings and physicians involved are rea-
sonably representative of the totality;
• To take account of all of the advantages and
disadvantages of the therapy, the physicians
and patients are not blinded to the therapy;
• All enrolled patients are followed under rou-
tine conditions; and
• A wide range of endpoints is measured; e.g.,
efficacy, feasibility, tolerance, quality of life,
resource use.
There are, however, disadvantages associated
with pragmatic trials. For example, the results that
they generate are still specific to the clinical/social/
geographical settings in which they are conducted.
Problems arise if it is necessary to repeat these
studies in several contexts, particularly when deci-
sion-makers are operating under a tight timetable.
This implies that pragmatic trials may not displace
the necessity of modeling, on the grounds that
modeling can produce cost-effectiveness estimates
in a timely manner [6].
 
The Design of the Studies Identified on HEED
 
Table 2 shows that approximately one-third of the
studies in our sample employed either an RCT or
modeling design (56/173).
The majority of studies in Table 2 are classified
as “primary observational.” The data in these
studies was collected alongside prospective or ret-
rospective nonrandomized trials. Thus, most of
the studies extracted from HEED were based on
methods that may not have the highest levels of
scientific validity. For this reason, we do not con-
sider these observational studies in any detail in
the following analysis, though it should be noted
that they may sometimes be of use in determining
practice patterns.
Table 2 also reports the study design used in the
pharmacoeconomic analyses (i.e., the economic
evaluation of pharmaceutical products). Such anal-
yses are the focus of most interest in a number of
countries; namely, those where there are require-
ments for the submission of economic data in sup-
port of claims for the public reimbursement of
pharmaceuticals. Australia and Ontario have had
these requirements for a number of years [8,9]. In
Europe, the Netherlands and Norway are among
those countries that will be introducing similar re-
quirements [10,11].
 
Pharmacoeconomic Studies
 
Pharmacoeconomic evaluations account for less
than half of all studies that employed RCT or
modeling methods (24 of 56). However, the evalu-
ation of pharmaceuticals comprises an even smaller
proportion of the primary observational studies (22
of 89). Therefore, perhaps unsurprisingly given the
common use of RCTs to evaluate the clinical effi-
cacy of pharmaceuticals, it appears more likely that
pharmaceuticals, compared to other forms of in-
tervention, will be evaluated in accordance with
the methods preferred by the US Panel and NICE.
Table 3 illustrates that some of the pharmaco-
economic evaluations falling into the category of
RCT-based or modeling studies do not deal with
interventions for the treatment of diabetes, but
with the treatment or prevention of the complica-
tions of diabetes, such as angiotensin converting
enzyme (ACE) inhibitors in diabetic nephropathy.
Moreover, some of the studies, whilst using dia-
betics as the patient group, are not related to dia-
betes or its complications. This further limits the
amount of currently available pharmacoeconomic
evaluation that is specifically related to the treat-
ment of diabetes.
 
Comparators, Outcomes and Time Horizon
 
Table 4 gives some indication of the comparators
and outcomes employed in the diabetes-related
pharmacoeconomic evaluations reported in Table
3. This table excludes the three studies in Table 3
that assess interventions directed at diabetics but
not relating specifically to diabetes. The informa-
tion in Table 4 suggests that the decision to use
modeling is not necessarily motivated by the need
or desire to include a range of comparators, since
no modeling study incorporated more than two
active pharmaceutical arms. Of note is that all of
the studies that included a nondrug technology
(e.g., screening for microalbuminuria/macropro-
teinuria) employed a modeling approach, perhaps
indicating a lack of RCT data on nondrug tech-
nologies.
 
Table 2
 
Study design
 
Primary
RCT Modeling
Primary
observational
Total
(including others)
All applied diabetes studies 24 32 89 173
Applied pharmacoeconomic studies 11 13 22 65
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Table 4 also reports the outcome measures used
in this sample of studies. In comparison with the
RCT-based studies which primarily report rela-
tively short-term clinical outcomes, a number of
the modeling studies provide estimates of life years
or QALYs gained. The limited sample in Table 4
thus suggests that studies based on modeling may
be more likely to report results of long-term out-
comes than studies based on RCT data. Moreover,
these outcomes potentially enable decision-makers
to make comparisons with interventions in other
disease areas.
The issue of short-and long-term outcomes has
arisen in the context of the recent UK Prospective
Diabetes Study (UKPDS).
 
The UKPDS
 
The study characteristics identified in Table 1 are
by no means an exhaustive list of the features rele-
vant to economic evaluation. However, as key is-
sues, their importance can be illustrated in the
context of type II diabetes. Table 1 indicates that
both the US Panel and NICE consider mortality
and quality of life measures as appropriate out-
comes. However, studies frequently report clinical
measures that have an undefined relationship with
survival or quality of life. In diabetes, recent data
from the UKPDS helps to illustrate this point with
respect to hemoglobin
 
A1c
 
, a commonly used mea-
sure of blood glucose control.
In the UKPDS34, it was found that people allo-
cated to metformin experienced a significant de-
crease in all-cause mortality relative to conven-
tional treatment, whilst those receiving intensive
control with chlorpropamide, glyburide or insulin,
despite similar changes in hemoglobin
 
A1c
 
, did not
[12]. Similarly, a significant reduction in mortality
was not found following intensive therapy with a
sulphonylurea (chlorpropamide, glyburide or glipiz-
ide) or insulin relative to conventional therapy in
the UKPDS33, despite reductions in hemoglobin
 
A1c
 
[13]. Moreover, based on the UKPDS data, Stratton
et al. have argued that their estimated epidemiologi-
cal relationships between hemoglobin
 
A1c
 
 and other
outcomes (e.g., a 14% decrease in all cause mor-
tality per 1% reduction in hemoglobin
 
A1c
 
 concen-
tration) may not be transferable to clinical prac-
tice [14].
The UKPDS serves to illustrate some of the ad-
vantages and disadvantages of a well-designed
RCT. It has features that could be regarded as ele-
ments of a pragmatic design. For example, it has
been noted that the study was unblinded, was con-
tinued when differences at the initial evaluation
were absent, and allowed patients treated with
diet to receive drug therapy under some circum-
stances [15]. It also included a range of compara-
tors, and was large enough, with a sufficiently
long period of follow-up, to show the macrovas-
cular advantages of metformin. The duration of
the study enabled the investigators in the eco-
nomic study UKPDS41 to “estimate long-term re-
source implications of type II diabetes and its
complications directly from trial data” [16].
At the same time, there were some protocol-
driven costs thought not to be typical of clinical
practice. In the economic analysis, an adjustment
was made for these costs. The absence of quality of
life information was less easy to control for, partic-
ularly for those years in which a patient did not ex-
 
Table 3
 
Diabetes-related pharmacoeconomic evaluations
 
Purpose of intervention Primary RCT Modeling
Treatment of diabetes 5 5
Treatment/prevention of complications of diabetes 4 7
Interventions directed at diabetics but not related to diabetes 2 1
 
Table 4
 
Interventions compared and outcome measures in the pharmacoeconomic evaluations
 
Primary RCT Modeling
One active pharmaceutical arm versus placebo/no treatment 2 4
Two active pharmaceutical arms 6 4
More than two active pharmaceutical arms 1 0
Pharmaceutical and other technology 0 4
Outcome measure
Clinical measures 9 7
Quality of life 2 1
Life years/expectancy 0 5
QALYs 0 5
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perience a clinical event but may have nevertheless
been suffering to some extent. It has been argued
that this is a potentially important aspect to adjust
for, particularly in a disease that is associated with
many complications, such as diabetes [16]. More-
over, the results of the study have become, to some
extent, less useful with the emergence of other
drugs for the treatment of type II diabetes.
 
Discussion
 
In the descriptive review presented in the first half
of this paper, it was reported that a large number
of articles relevant to the evaluation of interven-
tions against diabetes were identified from a
search of HEED, most of which contain some
original data. The number of studies undertaken
appears to have increased over time, and the ma-
jority are applicable to the USA. Most studies
were peer reviewed. The principal type of analysis
was cost-consequences, and the main foci of inter-
est were pharmaceutical and care services. The
government and the pharmaceutical industry were
the most likely sources of funding.
In the “compliance with guidance” section, an
attempt was made to identify the extent to which
the studies complied with some of the main rec-
ommendations of the US Panel and NICE. It was
noted that studies based on primary observational
data, which are regarded as a less preferred form
of evidence according to current guidance, form
the majority of applied studies. Narrowing the
search to RCT-based and modeling studies consid-
erably reduced the number of evaluations avail-
able for consideration. With a specific focus on
pharmacoeconomic analyses, modeling had evi-
dently been used to estimate the impact of health
care on longer-term generic outcomes, but had not
been used to broaden the range of comparators
compared to studies based on RCT data.
In the context of type II diabetes, the signifi-
cance of the outcomes and time horizon were illus-
trated with the UKPDS. While representing a land-
mark study in this disease area, the UKPDS perhaps
adds weight to the importance of modeling, since
decisions cannot normally be delayed for 20 years
whilst data from long-term RCTs is being collected.
A model dependent on information of lesser quality
may be acceptable if it gives better information
than that which is currently available. Also, by
making gaps in knowledge explicit, the modeling
process can help to identify areas for further re-
search and by testing the sensitivity of the results
to particular variables, modeling can highlight the
areas where reduced uncertainty would be most
beneficial. For those variables to which the results
are relatively insensitive, the costs of generating
data from an RCT may not be justified.
The distinction between RCT-based and mod-
eling studies should not be over-emphasized, since
models will ideally be based on the best available
evidence. The UKPDS, in addition to providing a
core data source from which the cost-effectiveness
of diabetes therapy has been directly estimated,
will provide raw data for future modeling exer-
cises. Judgement will always be required on the
merits and demerits of different study designs;
whatever method is chosen, the limitations of the
design should be recognized and the results inter-
preted with care.
 
The Office of Health Economics is partly funded by the
Association of the British Pharmaceutical Industry.
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